Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00635102 · ClinicalTrials.gov registry record · NA
Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 57
- Enrollment target
NCT00635102: Completed NA study, sponsored by Yale University.
NCT00635102 is a NA study that has completed, run by Yale University. The registered enrollment target is 57 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00635102, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 57 participants
- Enrollment target
Study Summary
Question #1: Will glycine ameliorate cognitive deficits? Hypothesis #1: Based on positive findings conducted with glycine and milacemide, a glycine prodrug, in schizophrenia and dementia, we expect that glycine will ameliorate cognitive deficits. Question #2: Will alcoholic patients show enhanced endocrinal effects to glycine? Hypothesis #2: Based on the dose-related effects of glycine in healthy subjects, we expect that glycine will increase the endocrinal response to glycine in alcoholic patients with, supposedly, dysregulated NMDA receptor function. Question #3: Will D-cycloserine have ethanol-like effects? Hypothesis #3: If inhibition of NMDA receptor function is fundamental to the subjective effects of ethanol, then the NMDA antagonist properties of D-cycloserine should be recognized as ethanol-like (relative to placebo) in recently detoxified alcoholics and healthy subjects. Question #4: Will D-cycloserine reverse cognitive benefits of glycine? Hypothesis 4: Based on the dose related NMDA antagonist activity of D-cycloserine, we expect that D-cycloserine will compete with the agonist activity of glycine and therefore it will reverse the cognitive benefits of glycine. Question #5: Will D-cycloserine inhibit endocrinal effects of glycine? Hypothesis #5: If the agonist activity of glycine is necessary to determine endocrine response, then the dose-related NMDA antagonist properties of D-cycloserine should block these effects.
Primary Outcome
Visual Analog Scales of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol -7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol
Interventions
- DRUG D-Cycloserine PO and Glycine IV
- DRUG Placebo D-Cycloserine PO and placebo Glycine IV
- DRUG Placebo D-Cycloserine PO and Glycine IV
- DRUG D-Cycloserine PO and placebo Glycine IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 1997-10 |
| Est. Completion | 2008-02 |
| Phase | NA |
What the finished NCT00635102 record still lists
NCT00635102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which D-Cycloserine PO and Glycine IV is the first listed.
NCT00635102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00635102 about?
NCT00635102 is a clinical study titled "Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects". Question #1: Will glycine ameliorate cognitive deficits? Hypothesis #1: Based on positive findings conducted with glycine and milacemide, a glycine prodrug, in schizophrenia and dementia, we expect that glycine will ameliorate cognitive deficits. Question #2: Will alcoholic patients show enhanced e...
What is the current status of trial NCT00635102?
This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 1997-10. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00635102?
The interventions under investigation include: D-Cycloserine PO and Glycine IV (DRUG), Placebo D-Cycloserine PO and placebo Glycine IV (DRUG), Placebo D-Cycloserine PO and Glycine IV (DRUG), D-Cycloserine PO and placebo Glycine IV (DRUG).
Who is sponsoring clinical trial NCT00635102?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00635102's enrollment target sits among peer trials
57 1261st of 2000 higher than 739 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia